Skip to main content

Advertisement

Table 2 Efficacy outcomes

From: Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

  No. of patients % 95%CI
All assessable patients 32   
 CR 3 9.4  
 PR 11 34.4  
 SD 11 34.4  
 PD 4 12.5  
 NE 3 9.4  
Overall response (CR + PR) 14 43.8 (26.5–61.0)
Clinical benefit rate (CR + PR + SD6 months) 18 56.3 (39.0–73.5)
Tumor control rate (CR + PR + SD) 25 78.1 (63.8–92.5)